Split History
ETFs Holding MBRX »    MBRX Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Moleculin Biotech is a clinical stage pharmaceutical company. Co.'s technologies include: Annamycin, an anthracycline designed to be different than existing approved anthracyclines by eliminating cardiotoxicity and avoiding the multidrug resistance mechanisms that can limit the efficacy of the approved products; WP1066 Portfolio, which includes WP1066 and WP1220, two of several Immune/Transcription Modulators in the portfolio designed to inhibit phosphorylated signal transducer and activator of transcription among other transcription factors associated with tumor activity, while also stimulating a natural immune response to tumors by inhibiting the errant activity of Regulatory T-Cells. According to our MBRX split history records, Moleculin Biotech has had 1 split.
MBRX split history picture
Moleculin Biotech (MBRX) has 1 split in our MBRX split history database. The split for MBRX took place on February 01, 2021. This was a 1 for 6 reverse split, meaning for each 6 shares of MBRX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 166.666666666667 share position following the split.

When a company such as Moleculin Biotech conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the MBRX split history from start to finish, an original position size of 1000 shares would have turned into 166.666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Moleculin Biotech shares, starting with a $10,000 purchase of MBRX, presented on a split-history-adjusted basis factoring in the complete MBRX split history. MBRX split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 06/03/2016
End date: 09/30/2022
Start price/share: $53.40
End price/share: $1.06
Dividends collected/share: $0.00
Total return: -98.01%
Average Annual Total Return: -46.17%
Starting investment: $10,000.00
Ending investment: $198.48
Years: 6.33
Date Ratio
02/01/20211 for 6
MBRX is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

MBVX Split History
MCK Split History
MD Split History
MDCI Split History
MDGL Split History
MDGN Split History
MDT Split History
MDVN Split History
MDXG Split History
MEIP Split History

Also explore: MBRX shares outstanding history

Email EnvelopeFree MBRX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

American Virtual Cloud Technologies, Inc. (AVCT)
Avenue Therapeutics, Inc. (ATXI)
Annaly Capital Management, Inc. (NLY)
CohBar, Inc. (CWBR)
TOP Ships Inc. (TOPS)
Sonnet BioTherapeutics Holdings, Inc. (SONN)
Nabriva Therapeutics plc (NBRV)
NeuroBo Pharmaceuticals, Inc. (NRBO)
First Wave BioPharma, Inc. (FWBI)
Palatin Technologies, Inc. (PTIN)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

MBRX Insider Buying

MBRX Split History | www.SplitHistory.com | Copyright © 2013 - 2022, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.